{"id":"ultra-long-gnrh-agonists-letrozole","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"40-60","effect":"Vaginal dryness"},{"rate":"30-50","effect":"Arthralgia/myalgia"},{"rate":"20-40","effect":"Headache"},{"rate":"15-30","effect":"Mood changes/depression"},{"rate":null,"effect":"Bone density loss"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1444","moleculeType":"Small molecule","molecularWeight":"285.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GnRH agonists desensitize the pituitary gland to suppress luteinizing hormone and follicle-stimulating hormone, thereby reducing ovarian estrogen production. Letrozole, an aromatase inhibitor, further blocks peripheral conversion of androgens to estrogen. This combination achieves profound estrogen deprivation, used primarily in hormone-sensitive breast cancer and endometriosis management.","oneSentence":"Ultra-long GnRH agonists suppress gonadal hormone production while letrozole blocks aromatase to inhibit estrogen synthesis, creating a dual hormonal suppression strategy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:00.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in premenopausal women"},{"name":"Endometriosis"}]},"trialDetails":[{"nctId":"NCT06985186","phase":"PHASE4","title":"Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2025-06","conditions":"Adenomyosis of Uterus, Infertility Assisted Reproductive Technology","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ultra-Long GnRH Agonists + Letrozole","genericName":"Ultra-Long GnRH Agonists + Letrozole","companyName":"University of Palermo","companyId":"university-of-palermo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ultra-long GnRH agonists suppress gonadal hormone production while letrozole blocks aromatase to inhibit estrogen synthesis, creating a dual hormonal suppression strategy. Used for Hormone receptor-positive breast cancer in premenopausal women, Endometriosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}